Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients.
OBJECTIVE
This study explored the self-management strategies utilized by female breast cancer patients to cope with the impact of chemotherapy-induced peripheral neuropathy (CIPN) symptoms. We also examined the variety of taxane-related side effects in women with and without CIPN in order to discriminate the CIPN symptom experience.


METHODS
A purposive sample of 25 patients treated with docetaxel or paclitaxel were recruited, half with and half without CIPN. Semistructured interviews and patient level data were utilized for this exploratory, descriptive study. Interview data were analyzed with the constant comparative method; patient level data were abstracted from the electronic medical record.


RESULTS
Participants were aged 24-60 years, were currently receiving chemotherapy or within 6 months of having completed treatment, and 14 had CIPN. CIPN impacted routine activities, functions, and behaviors in the areas of domestic, work, and social/leisure life. Multiple self-management and coping strategies to minimize the impact of CIPN symptoms were reported; the focus was on movement to reduce symptoms, attitude awareness, logistics to simplify demands, and environmental change. Women with and without CIPN were similar in the quantity and type of other reported side effects.


CONCLUSIONS
CIPN affects breast cancer patients' routine activities, functions, and behaviors, but they develop management strategies to reduce the impact. The management strategies reported in this study suggest breast cancer patients may adopt interventions that focus on exercise, mindfulness, occupational therapy, and environmental planning toward the goal of reducing the impact of CIPN symptoms on their lives.
Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA. speckr@mail.med.upenn.edu
Rebecca M
RM
Speck
Angela
A
DeMichele
John T
JT
Farrar
Sean
S
Hennessy
Jun J
JJ
Mao
Margaret G
MG
Stineman
Frances K
FK
Barg
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects; D010414:Pennsylvania; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D012648:Self Care / Q000379:methods*; D043823:Taxoids / Q000009:adverse effects; D055815:Young Adult
D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel